SALT LAKE CITY and TORONTO, Feb. 3,
2015 /PRNewswire/ -- EastGate Biotech Corp. (OTCBB:
ETBI), an emerging pharmaceutical company exploring drug delivery
innovations for the development of novel formulations and
alternative dosage forms of existing biologically active molecules
provides update on its patent portfolio for its sub-micron
self-nanoemulsifying platform technology.
The company recently expanded its new pharmaceutical product
development to include large molecules as active compounds that
will address indications in diabetes, obesity and the overall
metabolic syndrome. In order to protect our innovation and
know-how the company had filed these initial provisional
patents:
US 61/947,678 Title: Pharmaceutical Composition for
Transmucosal Delivery
US 61/947,698 Title: Treatment of Diabetes and
Metabolic Syndrome
These two provisional patents relate specifically to the
company's intraoral insulin formulation. The company has
outlined its sub-micron self-nanoemulsifying platform technology to
develop alternative dosage forms for delivery of known biologically
active molecules. These technological approaches have
demonstrated robustness and resulted in diversification of drug
delivery products. As a result, the company was able to
develop an intraoral insulin tablet that is delivered to the mouth
for intraoral insulin absorption (not GI-tract delivery).
The company will continue to prepare additional patent
application filings in order to bolster the intellectual property
and know-how of the intraoral insulin tablet and its other dosage
forms.
The company already has patents for its intraoral Lorazepam
Spray for acute seizures:
PCT/C2014/000126 Title: Pharmaceutical Composition
for Transmucosal Administration of Benzodiazepines
PCT/CA2014/000127 Title: Pharmaceutical Composition
For Enhanced Transmucosal Administration of Benzodiazepines
The company plans on expanding the patent portfolio for this
indication as the clinical and scale-up manufacturing development
continues.
"We are pleased with the expansiveness of our patent portfolio
for our pharmaceutical products", says Anna
Gluskin, CEO of EastGate Biotech Corp. "The company's
intent is to commercially-realize our unique sub-micron
self-nanoemusifying delivery system and the breadth of the
Intellectual Property will open the doors to licensing
partners interested in innovative drugs in the highly diverse
marketplace", continues Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact,
contained or incorporated by reference in this news release
constitute "forward-looking information" or "forward-looking
statements" within the meaning of certain securities laws,
including the provisions for "safe harbour" under the United States
Private Securities Litigation Reform Act of 1995 and are based on
expectations, estimates and projections as of the date of this news
release.
The words "anticipates", "plans", "expects", "indicate",
"intend", "scheduled", "estimates", "forecasts", "focus",
"guidance", "initiative", "model", "methodology", "outlook",
"potential", "projected", "pursue", "strategy", "study", "targets",
or "believes", or variations of or similar such words and phrases
or statements that certain actions, events or results "may",
"could", "would", or "should", "might", or "way forward", "will be
taken", "will occur" or "will be achieved" and similar expressions
identify forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that
are inherently subject to significant business, economic and
competitive risks, uncertainties and contingencies. The risks,
estimates, models and assumptions contained or incorporated by
reference in this release, include those identified from time to
time in the reports filed by EastGate with the SEC, which should be
considered together with any forward-looking statement.
EastGate undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eastgate-biotech-provides-update-on-its-patent-portfolio-300029657.html
SOURCE EastGate Biotech Corp.